Factor XIII-A in Diseases: Role Beyond Blood Coagulation by Dull, Katalin et al.
 International Journal of 
Molecular Sciences
Review
Factor XIII-A in Diseases: Role Beyond Blood Coagulation
Katalin Dull, Fruzsina Fazekas and Dániel Törőcsik *
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Abstract: Multidisciplinary research from the last few decades has revealed that Factor XIII subunit A
(FXIII-A) is not only involved in blood coagulation, but may have roles in various diseases. Here, we aim to
summarize data from studies involving patients with mutations in the F13A1 gene, performed in FXIII-A
knock-out mice models, clinical and histological studies assessing correlations between diseases severity
and FXIII-A levels, as well as from in vitro experiments. By providing a complex overview on its possible
role in wound healing, chronic inflammatory bowel diseases, athe-rosclerosis, rheumatoid arthritis, chronic
inflammatory lung diseases, chronic rhinosinusitis, solid tumors, hematological malignancies, and obesity,
we also demonstrate how the field evolved from using FXIII-A as a marker to accept and understand its
active role in inflammatory and malignant diseases.
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1. Introduction
In the plasma, Factor XIII is present as a heterotetramer (FXIII-A2B2), consisting of two
A subunits (FXIII-A) with catalytic activity and two B subunits (FXIII-B) that inhibit FXIII-
A by binding to it. During the coagulation cascade, thrombin cleaves off the activation
peptide from A subunit, the B subunit dissociates in a Ca2+-dependent manner, and FXIII-A
becomes an active transglutaminase cross-linking fibrin strands, accounting for its role in
stabilizing fibrin clots in the final stage of blood coagulation (reviewed in [1–4]).
Immunohistochemical detection later revealed that FXIII-A is also found intracel-
lularly (cFXIII-A) in various cell types, where it may be activated without proteolytic
cleavage by increased intracellular Ca2+ concentrations [5,6]. In the early embryonic
life, mesenchymal histiocytes and hepatocytes [7] stained positive for FXIII-A; in adult
life, megakaryocytes [8], platelets [9], monocytes [10,11], macrophages [10,12], dendritic
cells [13], chondrocytes [14–16], osteoblasts [17], preadipocytes [18], corneal keratocytes [19],
keratinocytes [20], fibroblasts [21], and sebocytes [22] all did as well. Importantly, detection
of FXIII-A is still routinely used as a marker in the histological diagnosis of a wide range
of inflammatory and malignant skin diseases (reviewed in [23]). Although some of the
reported positive stainings were later found to be dependent on the applied antibody [22],
while with the improvement of functional assays to distinguish macrophages from den-
dritic cells, FXIII-A became accepted as a marker of alternatively activated macrophages (a
subset which is important in tissue remodeling and not in the elimination of bacteria [24]),
rather than of dendritic cells [25–27]. These findings raised intriguing question on the
possible role for FXIII-A both intracellularly and in (patho)physiological conditions beyond
blood coagulation.
Factor XIII-A deficiency is mainly caused by mutations in the FXIII-A gene (95%
of cases) [28]; while homozygous mutations usually result in symptoms related to an
impaired blood coagulation, patients with heterozygous mutations are often asymptomatic.
Identification of patients with decreased or even diminished activity of FXIII-A and patients
with genetic variations (SNPs) in the gene F13A1 [29], as well as the generation of genetically
modified mouse models [30,31], has led the field into the era of proof-of-concept studies.
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Their characterization has demonstrated that indeed FXIII-A is not only involved in blood
coagulation, but may have a role in wound healing and in basic immunological functions
as well.
Implicating state-of-the art, unbiased research strategies and molecular methods
into FXIII-A research brought another breakthrough and opened new vistas to define its
relationship to diseases, many of which were not raised previously even at the level of
speculation. Whole gene expression profiling has revealed that in alternatively activated
macrophages, cFXIII-A may alter the expression of genes related to immune functions and
to wound response [32]; it has also shown that FXIII-A shows abundant expression levels in
adipose tissue, with a suggested role in adipose tissue development [33]. Protein detection
confirmed its possible intracellular substrate in the pathogenesis of atherosclerosis [34].
Modern “gene hunting”, using whole exome sequencing, has identified mutations in
FXIII-A to be the cause of familial dermatofibromas [35]. In addition, clinical studies
have found and explained correlations with its altered expression levels and disease
pathogenesis/severity in inflammatory diseases [36–42].
In this review, we aim to summarize the available results and our recent understanding
on the role of FXIII-A in various diseases (Figure 1).
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2. FXIII-A in Diseases
2.1. FXIII-A in Wound Healing
Patients diagnosed with FXIII-A deficiency often show impaired tissue repair [43,44].
This phenomenon was characterized by Inbal et al. in a transgenic mice model with a
targeted deletion of exon 7 in the F13A1 gene, where delayed re-epithelialization and
necrotized fissures were detected [45]. Importantly, when deficient mice were treated with
recombinant FXIII-A, wound healing was normal, suggesting a pivotal role for FXIII-A
from the plasma/extracellular space. The workgroup hypothesized that FXIII-A may
have a regulatory role in m ltiple aspects of wound healing: stabilize fibrin clots and
extracellular matrix, modulate monocyte functio s, promote angiogenesis, and upregulate
proangiogenic early growth response transcription factor 1 (Egr-1).
Angiogenesis nd ne vascularization also hav a central role in corn l wound healing.
Regarding FXIII-A in thi process, Orosz et al., using 16 corneas from 9 donors, showed that
corneal keratinocytes expressed FXIII-A, and measured elevated FXIII-A levels in human
tears following full-thickness corneal transplantation. Their findings have suggested
that FXIII-A in normal tears could be involved in the repair of micro-injuries, and the
increased FXIII-A concentrations observed after corneal transplantation may promote the
healing of surgical wounds. However, they also found that in higher concentrations, the
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effect of FXIII-A might become harmful by impairing fibrin elimination and enhancing
neovascularization [46].
Nahrendorf et al. aimed to determine the relationship between FXIII-A activity and
healing after myocardial infarction (MI) [47]. In a model of MI caused by left coronary
artery ligation, they observed impaired wound healing and fatal rupture of the left ventricle
in FXIII-deficient mice, while in wild-type mice a strong presence of FXIII-A positive cells
was detected, with increased transglutaminase activity within the healing injured tissue.
Replenishment of FXIII-A during the acute and subacute period restored survival rates,
confirming that FXIII-A may have a role in the prevention of cardiac rupture. Further
characterization of FXIII-A-deficient mice revealed an impaired inflammatory response,
marked by lipopolysaccharide-induced CXC (cysteine-X-cysteine motif) chemokine (LIX)-
and intercellular adhesion molecule-1 (ICAM)-independent neutrophil invasion, as well
as enhanced degradation of the extracellular matrix with impaired collagen synthesis.
However, FXIII-A re-substitution did not augment collagen synthesis in FXIII-A-deficient
mice, suggesting a complex role for FXIII-A, in which its intracellular form might be
involved as well.
2.2. FXIII-A in Chronic Inflammatory Bowel Diseases
Chronic inflammatory bowel diseases (CIBDs), e.g., Crohn’s disease (CD) and ulcera-
tive colitis (UC), are characterized by large wound areas and ulcerations, with spontaneous
hemorrhage in the intestines and the colon [48].
In an early study, Galloway et al. reported a markedly decreased Factor XIII-A
serum level in 6 out of 13 patients with CIBD [49], which was later confirmed by several
groups [50–53]. Studies further showed that FXIII-A levels were significantly lower in
patients with active than in those with inactive CD, which suggests that FXIII-A is asso-
ciated with disease activity [36,37]. However, in a study by Cougard et al., based on 129
patients’ data, although patients with CD had significantly lower FXIII-A serum levels
when compared to controls, when CD patients with flare-ups were compared to ones in
the remission phase, the difference did not reach the level of significance [54]. Moreover,
there was no correlation between lower FXIII-A levels and the length of flare-ups.
Several polymorphisms are known in the F13A1 gene [55], of which rs5985 is the most
common one, changing valine with leucine at position 34 (Val34Leu) near the thrombin acti-
vation site, causing faster FXIII-A activation and rapid fibrin clot formation [56,57]. Indeed,
the Val34Leu SNP of FXIII-A is associated with a reduced risk of venous thrombosis for
homozygous carriers [58]. Saibeni et al. examined the Val34Leu polymorphism distribution
and prevalence between 152 inflammatory bowel disease (IBD) patients and 130 healthy
controls, and found no difference between IBD and healthy volunteers [59]. This indicates
that the prothrombotic state described in IBD patients does not depend on the Val34Leu
polymorphism. Similarly, Heliö et al. observed no significant differences in the Val34Leu
polymorphism allele frequencies between 573 IBD patients and 142 controls [60].
When Soendergaard et al. evaluated the consequences of intestinal inflammation on
resident mucosal macrophages, focusing on the level and distribution of FXIII-A using
67 tissue samples from patients with active UC [61], they observed a decreased number
of FXIII-A/CD68/CD163-positive macrophages, suggesting a reduced phenotype of al-
ternative macrophage polarization and a consequent loss of cFXIII-A, in parallel with
decreased plasmatic FXIII-A (pFXIII-A) levels. The loss of cFXIII-A may impact migration
and phagocytosis, and hence limit pathogen eradication in UC.
Andersson et al., by examining colon samples from wild-type and FXIII-A deficient
mice following the induction of colitis, delivered results that have suggested that the loss of
FXIII-A may actively contribute to the pathogenesis of colitis, and could play an important
role in the repair of mucosal damage [38]. In their experiments, wild-type mice after
colitis-challenge had significantly decreased pFXIII-A levels, thus supporting previous
observations that pFXIII-A levels might be a reliable marker for active inflammatory
colitis. When examining the differences in the tissue damage of the colon, 25% of the
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colon samples from FXIII-A-deficient mice showed ulceration, while only 5% of wild-type
samples remained ulcerated in the colitis injury “resolution phase”.
Interestingly, some studies have suggested an important role also for the resident
intestinal flora in the pathogenesis of colitis in both humans and mice [62,63], assuming
that FXIII-A may support bacterial clearance by crosslinking bacterial surface proteins to
fibrin, thus limiting colitis severity [62,64,65].
2.3. FXIII-A in Atherosclerosis
Migration of monocytes into the arterial wall, and their transformation into lipid-rich
foam cells, is a pivotal step in the pathogenesis of atherosclerosis. Abdalla et al. showed
that angiotensin II-induced cFXIII-A activation facilitates the covalent cross-links between
type 1 angiotensin receptor monomers, resulting in enhanced signaling and desensitization.
This finding was associated with increased adhesion of monocytes to the endothelium in
ApoE-deficient mice [33], which is one of the earliest detectable changes in atherosclerotic
lesions (reviewed in [66]).
Microarray experiments also found upregulated expression of FXIII-A mRNA in
peripheral blood cells from five coronary artery disease patients [67]. As a possible ex-
planation, in human monocytes FXIII-A was shown to be involved in processes related
to atherogenesis, such as receptor-mediated phagocytosis [68] or the remodeling of small
arteries after a reduction in blood flow in mice [69].
According to the results of Naito et al., FXIII-A cross-linked fibrin-enhanced vascular
smooth muscle cell migration in vitro. Since the migration of vascular smooth muscle cells
to the intima is a key event during the pathogenesis of atherosclerosis, this finding further
strengthens the role of FXIII-A in the development of atherosclerosis [70].
2.4. FXIII-A in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disorder, primar-
ily affecting the joints, causing synovial hyperplasia and tissue destruction. As a result,
irreversible cartilage and bone destruction may occur. A link between an altered blood
coagulation system and RA has been reported [71–74], suggesting a direct correlation be-
tween reduced levels of coagulation factors, increased levels of fibrin degradation products,
and RA disease progression by local inflammation and altered osteoclast function.
Raghu et al. examined the possible role for FXIII-A in RA pathogenesis. Previously,
they had reported that fibrinogen may contribute to collagen-induced arthritis (CIA) disease
progression in mice by binding the leukocyte integrin receptor ↵M 2, thus inducing local
inflammation [75]. They revealed that in FXIII-A-deficient mice, bone and cartilage erosion
was diminished when compared with FXIII-A wild-type littermate controls [76]. Examining
the knee joints of FXIII-A-deficient mice, an altered pattern of fibrin deposition with
decreased numbers of inflammatory cells and reduced levels of IL6 (interleukin 6) and IL1 
proinflammatory cytokines were observed. Interestingly, lower osteoclast numbers and
activity linked to deficient receptor activator of NFB ligand (RANKL)-induced osteoclast
formation was also found in FXIII-A deficient mice. Providing further evidence, the
pharmacological inhibition of transglutaminase activity diminished the development of
arthritis and osteoclastogenesis in wild-type mice, suggesting that targeting FXIII-A (and
its transglutaminase activity) may provide an attractive therapeutic strategy to control
inflammation, cartilage, and bone destruction in RA.
2.5. FXIII-A in Chronic Inflammatory Lung Diseases
Bronchiolar and alveolar fibrin deposition is known as a hallmark of acute and chronic
inflammatory lung diseases [77]. Katona et al. determined cellular and plasmatic FXIII-
A levels and their correlation with levels of D-dimer, a breakdown product of cross-
linked fibrin, from bronchoalveolar lavage fluid (BALF) of 39 pediatric patients with
bronchoalveolar inflammation [39]. They found that cFXIII-A, pFXIII-A, and D-dimer
levels were significantly elevated in patient samples when compared to control ones;
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moreover D-dimer levels correlated also with neutrophil counts. Based on their findings
that in BALF samples, FXIII-A was exclusively expressed in alveolar macrophages, they
concluded that FXIII-A, which could be an important regulator of fibrin turnover in the
extravascular compartment, might be released from activated alveolar macrophages.
Esnault et al. examined the possible association between FXIII-A and asthma, finding
that FXIII-A expression correlated with increased airflow limitation [40]. Analyzing FXIII-A
mRNA and protein levels in the BALF from seven patients before and after an allergen
challenge, they found significantly upregulated FXIII-A levels in brochoalveolar cells
after allergen exposure. As FXIII-A mRNA expression levels were found to be positively
correlated with a type 2 immune response and mRNA levels of CD207 (marker for dendritic
cells) and CD209 (marker for dendritic cells and alternatively activated macrophages),
immune cells were suggested to be the main source of FXIII-A also in the BALF of asthma
patients, with a possible role in enhancing airway obstruction.
2.6. FXIII-A in Chronic Rhinosinusitis
Chronic rhinosinusitis (CRS) is a clinically heterogeneous group, characterized by
persistent inflammation of the upper airways. Based on clinical symptoms and histological
findings, CRS is classified into two groups: CRS without and with nasal polyps (CRSsNP
and CRSwNP, respectively). While sinonasal tissue samples of CRSsNP patients show
a predominant infiltration of neutrophils with the presence of Th1 (T helper cell type 1)
cytokines, CRSwNP samples show eosinophilic infiltration and a Th2-based cytokine
profile [78], which is a strong inducer of FXIII-A expression in alternatively activated
macrophages [25].
In CRSwNP samples, excessive fibrin deposition and low D-dimer levels were de-
tected, suggesting reduced fibrinolysis, which may contribute to tissue remodeling and
the progression of the disease. However, in spite of the prominent inflammation, tissue
samples of nasal polyps showed low levels of fibrosis [79]. Further findings, detecting
increased FXIII-A levels in nasal polyp tissues of CRSwNP patients concluded that FXIII-A
derived from alternatively activated macrophages might be involved in the formation
of fibrin deposits in nasal polyps. Overexpression of FXIII-A therefore may lead to the
acceleration of the coagulation cascade, resulting in fibrin deposition, tissue remodeling,
edema, or pseudocyst formation of the submucosa, thus promoting disease progression.
The results of the workgroup put forward that targeting FXIII-A production of alternatively
activated macrophages might have therapeutic potential for CRSwNP patients [80].
2.7. FXIII-A in the Tumor Microenvironment
2.7.1. Solid Tumors
As reviewed by Pollard [81], tumor-associated macrophages (TAMs) populate the mi-
croenvironment in most solid tumors, with a possible contribution to clinical outcomes by
affecting several processes during tumorigenesis, from tumor initialization to the formation
of metastases. Importantly, in a great number of tumors, TAMs (as a type of alternatively
activated macrophages) have been reported to be FXIII-A positive [82–84]. Based on the
fact that FXIII-A stabilizes fibrin networks, it is reasonable to suppose that (TAM-derived)
FXIII-A may have an important role also in the formation of tumor matrix fibrin deposits,
which may facilitate tumor matrix generation and tumor progression [85].
Palumbo et al. reported that the metastatic potential of intradermally injected B16-BL6
melanoma cells after 12–13 days was diminished in FXIII-A-deficient mice. They found
that FXIII-A was not required for the growth of tumors or stroma formation, but supported
the early survival of micrometastases by stabilizing fibrin/platelet thrombi associated
with the newly formed micrometastases, thus limiting natural killer cell (NK)-mediated
clearance of tumor cells. Moreover, the genetic elimination of FXIII-A transglutaminase
activity significantly reduced lung and hematogenous metastases [86].
Vairaktaris et al. performed genetic analysis of oral squamous cell carcinoma samples
from 130 patients. They found that the Val34Leu SNP occurred frequently, which may
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cause a thinner fibrin network due to an altered FXIII-A activation in carcinoma samples.
Their findings suggested that the Val34Leu polymorphism is associated with an increased
risk for oral squamous cell carcinoma, but not with its progression and metastasis [87].
Porrello et al. [41] identified a subset of lung squamous cell carcinoma tumors, charac-
terized by the dense infiltration of inflammatory monocytes (IMs)/TAM precursors that
correlate with poor survival, based on the examination of 491 samples. They showed that
chemokine ligand 2 (CCL2)-mediated IMs expressed high levels of FXIII-A, which could
promote fibrin cross-linking to create a scaffold for carcinoma cell invasion and metas-
tases. The presence of cross-linked fibrin in the tumor microenvironment is correlated with
poor survival.
2.7.2. Dermatofibromas
Dermatofibromas (DF) are common, benign fibro-histiocytic tumors characterized by
the presence of fibroblasts, macrophages, and multinucleated giant cells [88]. Firstly, Cerio
et al. demonstrated by immunohistochemical staining of 30 patient samples that numerous
dermal cells of DF samples react with anti-FXIII-A antibodies [89], which (together with
the hematopoietic stem cell marker CD34) gained importance in the differential diagnosis
for dermatofibrosarcoma (DFSP), where tumor cells were negative for FXIII-A and positive
for CD34 [90–92].
In seven individuals from two unrelated families, with multiple dermatofibromas
inherited in an autosomal dominant pattern, Supsrisunjai et al. revealed a missense vari-
ant in the FXIII-A gene (c.2036A>T; rs201302247) by using whole exome sequencing [35].
This mutation was the only variant in all affected individuals with multiple dermatofi-
bromas. Moreover, they found that this mutation in FXIII-A led to reduced crosslinking
activity, promoted cell proliferation via mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3 kinase (PI3K) activation, altered collagen production, and showed a
higher association with a4b1 integrins on fibroblasts compared to control samples. These
findings provided solid evidence that FXIII-A is not only a useful immunohistochemical




FXIII-A expression was observed in circulating monocytes of 48 acute non-lymphoid
leukemia (ANLL) patients by Invernizzi et al. [93]. A positive correlation was shown
between the presence of FXIII-A and the expression markers of the monocytes, suggesting
that FXIII-A may be considered also as a molecular marker of monocyte differentiation.
They also confirmed the previous findings of Ádány et al. [94] that its synthesis starts in
the early stage of monocytopoiesis, along with alpha naphthyl acetate esterase (ANAE),
sometimes earlier than CD14 (marker of the of the myelomonocyte lineage). Since its
expression is directly related to the cell type and maturation degree, its detection may be a
useful tool in the characterization of acute leukemia (AL) [95], alongside traditional and
immunological markers.
On the basis of FXIII-A expression in 49 pediatric B-cell progenitor acute lymphoblas-
tic leukemia (BCP-ALL) patients, Gyurina et al. identified new subgroups and described
first B-cell precursor blasts as FXIII-A-expressing cells [96]. The three subgroups, according
to FXIII-A cytoplasmic expression patterns of lymphoblasts as revealed by flow cytometry
(FXIII-A-negative; FXIII-A dim: a uniformly positive population, but with lower mean
fluorescence intensity than the positive control cells; and FXIII-A bright: uniformly positive
population with higher fluorescence intensity than the control), had distinct gene expres-
sion profiles as well. The study of Kárai et al., based on 55 pediatric patient samples, found
that the FXIII-A negative subgroup had and unfavorable disease outcome, with worse
event-free and overall survival compared to patients with FXIII-A-positive blasts [42],
while an excellent correlation was seen between FXIII-A positivity and long-term sur-
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vival. It is hypothesized that in the absence of FXIII-A, the migration of lymphoblasts
from the osteoblastic niche (inner surface of the bone cavity) to the vascular niche might
be limited [97]. Since immuno- or chemotherapeutic drug-mediated cell death is more
pronounced in the vascular niche, FXIII-A negative lymphoblasts retained in the bone
cavity may survive more. In conclusion, FXIII-A expression could be a useful diagnostic
marker to identify cases that require further genetic examination and a prognostic factor in
childhood BCL-ALL.
Hodgkin Lymphoma
In the lymph nodes of Hodgkin lymphoma patients, where fibrin deposits are a general
observation [98], Ádány et al., examining 12 Hodgkin lymphoma samples, identified a
unique FXIII-A-expressing cell type with macrophage origin [99]. These cells showed
macrophage marker Leu M3 and ANAE positivity, but they were negative for HLA-DR,
AcP, ALP, and ATPase, suggesting that this FXIII-A-positive cell type is different from
any other macrophage cell type identified earlier in human lymph nodes. The authors
concluded that FXIII-A-positive macrophages in Hodgkin lymphoma samples may have a
function in malignant cell proliferation.
2.8. FXIII-A and Obesity
A genome-wide association study identified F13A1 as the gene with the most abundant
expression levels in the white adipose tissue of obese individuals. In addition to this, seven
SNPs in the F13A1 gene were linked to obesity, suggesting that FXIII-A may have an
important regulatory role in adipose tissue biology [100].
Further studies examining weight-discordant monozygotic twins in association with
FXIII-A expression have found that FXIII-A was the only transglutaminase with signif-
icantly elevated expression levels in adipose tissue of the heavier twin. They found
that FXIII-A mRNA levels increased with weight gain and were associated with pro-
inflammatory, cell stress, and tissue remodeling pathways, supporting its role in adipose
tissue expansion and inflammation linked to obesity. Interestingly, they have also found a
positive correlation between the expression of FXIII-A and phospholipase 2A (PLA2G16)
and mitogen-activated protein kinase 1 (MAPK1) genes; both genes are shown to be in-
volved in lipolysis. Based on these findings, Kaartinen et al. suggested that FXIII-A could
be an important therapeutic target to control adipose tissue inflammation linked to human
obesity [33,101].
Investigating the role of transglutaminase activity in adipogenesis, Myneni et al.
demonstrated, using FXIII-A-deficient mice, that differentiating preadipocytes have abun-
dant transglutaminase activity, which may be derived from FXIII-A [18]. Importantly,
besides fibrin, fibronectin expressed in white adipose tissue—where it may have a regula-
tory role in cell proliferation, differentiation, and adipogenesis [102–105]—is an important
extracellular substrate for FXIII-A [106]. Myneni et al. showed that the FXIII-A expres-
sion in mouse 3T3-L1 cell-derived preadipocytes negatively regulates adipogenesis by
increasing plasma fibronectin matrix assembly, promotes preadipocyte proliferation, and
increases the pro-proliferative effects of insulin, thus suggesting a new role for FXIII-A in
energy metabolism.
In a follow-up study, high-fat diet induced insulin resistance and hyperinsulinemia
in wild-type but not in FXIII-A deficient mice. Moreover, FXIII-A deficient mice, despite
gaining the same bodyweight as wild-type control animals, showed metabolically healthy
obesity with healthy adipose tissue expansion, as marked by an increase in the size of
adipocytes, proliferation, reduced white adipose tissue inflammation, and lower plasma
triglyceride levels. Based on these findings, FXIII-A may have a regulatory function in
obesity, and thus could be an important molecular target to improve the metabolic profile
and regulate insulin resistance [107].
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3. Conclusions
Although the number of inflammatory and malignant diseases in which FXIII-A is
suggested to be involved has increased, in most cases our knowledge on its possible
role in disease development is still at the level of speculation. FXIII-A may play a role
as a coagulation factor, altering clot stabilization and bleeding, just like an enzyme in
the extracellular space that is able to cross-link proteins, such as fibronectin, vitronectin,
osteopontin, thrombospondin, and certain adhesive glycoprotein components of the extra-
cellular matrix [108–111]. Furthermore, especially in diseases where alternatively activated
macrophages are potentially involved, FXIII-A may have a possible role as an intracellu-
lar/secreted enzyme as well. Considering the wide range of diseases, questions remain
open on how these features of FXIII-A, alone or in combination, may contribute to disease
pathogenesis and progression, and perhaps may link diseases of which many have nothing
else in common but FXIII-A. In providing answers, and further start points, not only basic
and clinical research but registry-based [29] epidemiological studies should gain focus
as well.
Another intriguing question is how FXIII-A could be used for therapies. While its
application in dermal histopathological diagnosis has stood the test of time, in clinical
practice FXIII-A is used only for substitution therapies of FXIII-A deficient patients [112].
Although the high cost of recombinant FXIII-A is indeed a limiting factor, trials are needed
to test how the results of animal studies and in vitro experiments could be translated into
human settings. Importantly, further therapeutic approaches should also be assessed, such
as altering the levels and activity of FXIII-A in the local microenvironment. While devel-
oping and selectively delivering specific inhibitors for FXIII-A on site may modulate its
unwanted effects [113], identifying stimuli that could be applied to regulate the production
and secretion of cFXIII-A into the local microenvironment may utilize its beneficial ones.
In summary, although our knowledge has improved significantly, it appears that there
are still ample ways, such as exploring new diseases and applying novel methods, to go on
in order to reveal the (patho)physiological effect of FXIII-A in full, and importantly, how
that can be applied in future therapies.
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